Hologic Inc

Hologic Inc (HOLX) Stock Analysis

$76.010

+0.365 (+0.48%)At close

Loading chart…
High
76.070
Open
76.010
VWAP
76.03
Vol
102.03M
Mkt Cap
17.32B
Low
76.000
Amount
7.76B
EV/EBITDA, TTM
13.12

Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm.

AI analysis of Hologic Inc (HOLX)

hold

Hologic Inc (HOLX) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. While the technical indicators are mildly positive, the lack of significant positive catalysts, a recent analyst downgrade, and declining financial metrics suggest a cautious approach. Holding the stock or exploring other opportunities may be more prudent.

Analyst Ratings (19)

+2.04% upside
Buy
14 Buy
5 Hold
0 Sell
Current: 76.01
Low
76.00
Average
77.56
High
79.00

Evercore ISI

2026-01-05

Price Target

$78

In Line

BNP Paribas Exane

2025-11-21

Price Target

$79

Neutral

Morgan Stanley

2025-11-10

Price Target

$76

Equal Weight

Mizuho

2025-10-23

Price Target

$78

Neutral

Stephens

2025-10-22

Price Target

$76

Equal Weight

Valuation Metrics

The current forward P/E ratio for Hologic Inc (HOLX) is 16.75, compared to its 5-year average forward P/E of 18.03.

Forward P/E

Fair
5Y Average P/E
18.03
Current P/E
16.75
Overvalued
21.07
Undervalued
15.00

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
13.42
Current EV/EBITDA
13.12
Overvalued
15.33
Undervalued
11.52

Forward P/S

Fair
5Y Average P/S
4.26
Current P/S
3.81
Overvalued
4.80
Undervalued
3.73

Alphio AI Price Scenarios for HOLX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%HOLX

$90.01

Scenario price

B

Base

Base · 50%HOLX

$75.18

Scenario price

B

Bear

Bear · 25%HOLX

$64.21

Scenario price

Whales holding HOLX

M

MIV Asset Management AG

+ HoldingHOLX

+11.46%

3M Return

C

Cinctive Capital Management LP

+ HoldingHOLX

+5.13%

3M Return

A

Alberta Investment Management Corporation

+ HoldingHOLX

+4.48%

3M Return

Q

Quinn Opportunity Partners LLC

+ HoldingHOLX

+3.48%

3M Return

M

Manulife Asset Management

+ HoldingHOLX

+3.16%

3M Return

S

Soros Fund Management LLC

+ HoldingHOLX

+2.88%

3M Return

Events Timeline

2026-06-16 (ET)

13:30:00

Hologic Wins in Germany, Siemens Prohibited from Selling Mammography Systems

2026-04-07 (ET)

09:30:00

Hologic Completes Acquisition by Blackstone and TPG, Valued at Up to $79 per Share

2026-04-06 (ET)

17:20:00

Blackstone and TPG to Acquire Hologic, Deal Expected by April 7

17:20:00

Blackstone and TPG Acquire Hologic, Deal Expected by April 7

News

HOLX FAQ — answered by Alphio AI

Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm. It operates in the Healthcare sector (X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPA industry).

Hologic Inc (HOLX) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. While the technical indicators are mildly positive, the lack of significant positive catalysts, a recent analyst downgrade, and declining financial metrics suggest a cautious approach. Holding the stock or exploring other opportunities may be more prudent.

19 analysts cover HOLX: 14 rate it Buy, 5 Hold and 0 Sell. The average price target is 77.56.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started